Nuclear medicine aids early diagnosis of pulmonary anthrax

December 11, 2001

Reston, VA - A nuclear medicine procedure that has the potential to safely pinpoint even the smallest amounts of infected tissue has received preliminary approval for a clinical trial in the diagnosis of inhalation anthrax before symptoms become apparent. A report on this possible breakthrough will appear in the Newsline section of the December issue of The Journal of Nuclear Medicine, available on December 19. The Newsline article can be found at: http://www.snm.org/pdf/newslinecurr.pdf

The JNM Newsline reports that the Food and Drug Administration (FDA) has approved a protocol for a clinical trial to assess the efficacy of a 99mTc-labeled monoclonal antibody in imaging early-stage inhalation anthrax infection.

According to the representatives of the company that has developed the monoclonal antibody, the technique offers the unique ability to detect the earliest stages of involvement, before any other laboratory or radiographic diagnostic tests can detect the presence of infection and well before the more serious symptoms of inhalation anthrax infection are apparent. Newsline reports that the technique promises not only to identify and begin treatment for patients in the earliest stages of infection but to provide a means by which patients can be definitively identified as disease free and taken off long-term wide-spectrum antibiotic treatment.

According to Newsline, the protocol, developed by Robert Bridwell, MD, Associate Professor of Nuclear Medicine and Radiology and the Uniformed Services University of the Health Sciences (Bethesda, MD) and staff physician at Walter Reed Army Medical Center (WRAMC; Washington, DC), is designed to identify asymptomatic patients who have experienced "credible exposure" to anthrax spores. Information from Bridwell obtained by SNM after the article went to press, indicated that all patients exposed will be assessed and that for ethical reasons there will not be a control group. The trial will be undertaken with patients that are on active military duty, their spouses, or retired individuals.

Bridwell is quoted in the Newsline article as stating, "Once anthrax spores were discovered in the United States, there was a real urgency to scour the various methods that currently exist to determine whether any offered promise in the early diagnosis of anthrax infection." As of the date of this press release, no patients have been imaged. "The good news is we currently don't have patients who need to be part of this protocol," said Bridwell. "The better news is that we have additional testing opportunities to try should the need arise."

Newsline notes that an Investigational New Drug (IND) approval was granted for the trial in two to three weeks, which may be record time. Individuals from academic medicine, the military, government agencies, and industry worked together to secure the IND.

Palatin Technologies (Princeton, NJ) is the maker of the radiolabeled antibody product, Leutech™, that will be used in the WRAMC investigation and is the company to which the IND was granted. Newsline notes that Palatin is a development-stage biopharmaceutical company that began work with what would become known by the trade name of LeuTech in 1996. The 99mTc-labeled monoclonal antibody binds with high affinity and specificity to a carbohydrate antigen, CD-15, on human polymorphonuclear leukocytes in vivo. This ability means that, once a small amount of the radiolabeled antibody is injected, it binds to white blood cells congregating at the site of even the earliest infections and makes them apparent on nuclear medicine imaging. The technique has been tested successfully in functional imaging of other infections, including appendicitis, osteomyelitis, bowel infections, and postsurgical infection.

In the article, Mathew Thakur, PhD, Professor of Diagnostic Radiology and Nuclear Medicine at Thomas Jefferson University (Philadelphia PA), notes that "With its high specificity and affinity--and a number of other advantages--this technique provides a logical and promising approach to early diagnosis, which assumes critical importance in an entity as life-threatening as anthrax and where criminal activity may be involved." Thakur was the earliest nuclear medicine practitioner to work with this radiolabeled antibody.

Bridwell agrees, noting that "this technique also reinforces nuclear medicine's growing importance in providing fast and reliable functional information at the cellular diagnostic level."

According to the article, should the initial results of this clinical trial demonstrate the monoclonal antibody's utility in the diagnosis of inhalation anthrax, Palatin will initiate discussions with the FDA to provide the agent to other medical institutions caring for patients with credible exposure to anthrax.
-end-
Contacts:
Reporter for the Newsline Article: Nancy Knight, PhD, Society of Nuclear Medicine Consulting Newsline Editor, 301-495-0056

To arrange interviews with Dr. Bridwell and the Walter Reed staff:
Jim Swisher
Public Affairs Officer
Walter Reed Army Medical Center
Washington, DC
202-782-7177

For background on the development and applications of the radiolabeled antibody technology:
Mathew Thakur, PhD
Director, Radiopharmaceutical Research
Thomas Jefferson University Hospital
Philadelphia, PA
215-503-7874

For additional information on LeuTech and for still images and B-rolls:
Stephen T. Wills
Palatin Technologies
609-520-1911
swills@Palatin.com or
Joan Kureczka
Kureczka/Martin Associates
415-821-2413
jkureczka@aol.com

Copies of the December and past issues of The Journal of Nuclear Medicine are available online at http://www.jnm.snmjournals.org. Print copies can be obtained at $15 per copy by contacting the SNM Service Center, Society of Nuclear Medicine, 1850 Samuel Morse Drive, Reston, VA 20190-5315; phone: 703-326-1186; fax: 703-708-9015; e-mail: servicecenter@snm.org. A yearly subscription to the journal is $170. A journal subscription is a member benefit of the Society of Nuclear Medicine.

Society of Nuclear Medicine

Related Infection Articles from Brightsurf:

Halving the risk of infection following surgery
New analysis by the University of Leeds and the University of Bern of more than 14,000 operations has found that using alcoholic chlorhexidine gluconate (CHG) halves the risk of infection in certain types of surgery when compared to the more commonly used povidone-iodine (PVI).

How plants shut the door on infection
A new study by an international team including University of Maryland scientists has discovered the key calcium channel responsible for closing plant pores as an immune response to pathogen exposure.

Sensing infection, suppressing regeneration
UIC researchers describe an enzyme that blocks the ability of blood vessel cells to self-heal.

Boost to lung immunity following infection
The strength of the immune system in response to respiratory infections is constantly changing, depending on the history of previous, unrelated infections, according to new research from the Crick.

Is infection after surgery associated with increased long-term risk of infection, death?
Whether experiencing an infection within the first 30 days after surgery is associated with an increased risk of another infection and death within one year was the focus of this observational study that included about 660,000 veterans who underwent major surgery.

Revealed: How E. coli knows how to cause the worst possible infection
The discovery could one day let doctors prevent the infection by allowing E. coli to pass harmlessly through the body.

UK study shows most patients with suspected urinary tract infection and treated with antibiotics actually lack evidence of this infection
New research presented at this week's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, Netherlands (April 13-16, 2019) shows that only one third of patients that enter the emergency department with suspected urinary tract infection (UTI) actually have evidence of this infection, yet almost all are treated with antibiotics, unnecessarily driving the emergence of antimicrobial resistance.

Bacteria in urine doesn't always indicate infection
Doctors should think carefully before testing patients for a urinary tract infection (UTI) to avoid over-diagnosis and unnecessary antibiotic treatment, according to updated asymptomatic bacteriuria (ASB) guidelines released by the Infectious Diseases Society of America (IDSA) and published in Clinical Infectious Diseases.

Subsidies for infection control to healthcare institutions help reduce infection levels
Researchers compared three types of infection control subsidies and found that under a limited budget, a dollar-for-dollar matching subsidy, in which policymakers match hospital spending for infection control measures, was the most effective at reducing the number of hospital-acquired infections.

Dengue virus infection may cause severe outcomes following Zika virus infection during pregnancy
This study is the first to report a possible mechanism for the enhancement of Zika virus progression during pregnancy in an animal model.

Read More: Infection News and Infection Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.